Posts filtered by tags: Shire[x]


A Guide To Guruguru Brain, The Gate To The Best Of The Asian Underground

Kikagaku Moyo hail from Tokyo, but they might as well descend from Atlantis, Oz, and the Shire all at once. A mighty five-piece that blend multiple guitars with a hodgepodge of pedals alongside a roving sitar, the band threads an evocative reinterpretation of stoner rock as something more worldly, ambient, and atmospheric. They're … More »
Tags: Music, Tokyo, Shire, Sounding Board, Kikagaku Moyo, Go Kurosawa, Guruguru Brain, J. William Parker, Khana Bierbood, Minami Deustch, Nawksh, Ramayana Soul, Scattered Purgatory, Sundays & Cybele, Tengger

Mythic Guide to Heroes & Villains — The Hero Archetype and the Hero’s Journey

This is Part 2 of the Mythic Guide to Heroes & Villains. The Hero Archetype An archetype, in simplified terms, is essentially a defining quality or qualities that summarize a character into a label. One of these is “hero.” The hero is an archetype for a character, as is the anti-hero, the villain, the mentor, the side-kick, and so forth. While it is important for your characters to be original, many writers still elect to utilize these well-known archetypes. These already well-established arc...
Tags: New York, Character Development, Harry Potter, Shire, Middle Earth, Luke Skywalker, Frodo Baggins, Mythic Guide to Heroes and Villains, Michel Corleone

Lanny ~ Max Porter

I seem to recall I made some pronouncement (an observation rather than a criticism) somewhere back in 2016 about how much I struggled with this... Not with the book, though I was so slow to realise that Grief is the Thing With Feathers was a novel and not a memoir, that it took hearing Max Porter talk about the book at Port Eliot Festival for the penny to drop. I had an odd few days afterwards trying to square it all in my it was the paperback cover that I had a bit of an issue wit...
Tags: Books, London, Dart, Shire, South West, Douglas, Ted Hughes, Charles Causley, Faber, Lanny, Dovegreyreader, 2019, Alice Oswald, Max Porter, Nan Shepherd, Lanny ~ Max Porter

‘Treehouse’ May be the Best (and Certainly the Most Topical) ‘Into the Dark’ Entry Yet

(Blumhouse Television and Hulu have partnered for a monthly horror anthology series titled Into The Dark , set to release a full holiday-themed feature the first Friday of every month. Horror anthology expert Matt Donato will be tackling the series one-by-one, stacking up the entries as they become streamable.) Blumhouse and Hulu’s Into The Dark series strategically kicked off with a string of prominent holidays – Halloween clear through Valentine’s Day – but March poses a definition-less...
Tags: Television, Movies, Horror, Features, Movie Reviews, Wheeler, Shire, Hulu, Treehouse, Peter, Gwen, Kara, Simpson, Agnes, Blumhouse, Charlie Campbell

Rani’s “Robotic Pill” for Biologics Clears First Hurdle in Humans

Swallowing a pill is a convenience that’s not available for all drugs. The cells and proteins in biological therapies can’t survive digestive enzymes, whose role is to break things down. That’s why insulin and other biologics must be injected.But what if there were a pill you could swallow that administers the injection inside your body? That’s the idea behind Rani Therapeutics, a medical technology company that has developed a “robotic pill” and is financially backed by some of world’s biggest...
Tags: Google, Startups, Drugs, San Francisco, Trends, Astrazeneca, Fda, Novartis, Shire, Biotech, Insulin, Medical Device, Alphabet, Life Sciences, Drug Delivery, Clinical Trials

Blackstone Life Sciences invests $250 mln in Anthos Therapeutics

Blackstone Life Sciences said Feb. 27 that it launched Anthos Therapeutics Inc, a biopharmaceutical company focused on advancing targeted therapies for high-risk cardiovascular patients. Blackstone is investing $250 million in Anthos. Novartis will have a minority. PRESS RELEASE CAMBRIDGE, Mass.–(BUSINESS WIRE)–Blackstone Life Sciences today announced the launch of Anthos Therapeutics Inc. (“Anthos”), a new biopharmaceutical company focused on advancing next-generation targeted therapies for hig...
Tags: Trends, Novartis, Shire, Blackstone, Baxalta, Cambridge Massachusetts, Paris Panayiotopoulos, Executive Team, Ariad Pharmaceuticals, Clarus, Jonathan Freeman, Novartis Institutes for BioMedical Research, Glasspool, JAy Bradner, Blackstone Life Sciences, Nick Galakatos

Oyster Point Gets $93M To Clear Up Dry Eye With a Nasal Spray

Dry eye disease affects millions of people in the U.S., and while several treatments, mostly eye drops, are available, they all have flaws. An emerging startup called Oyster Point Pharmaceuticals is trying a completely different approach—a nasal spray that coaxes the body into making tears. And the company just got enough cash to get that treatment to market, if its final clinical tests are a success.Oyster Point, a Princeton, NJ startup led by former Ophthotech (NASDAQ: OPHT) executive Jeffrey...
Tags: Deals, Startups, New York, Trends, Vc, Allergan, Shire, New Enterprise Associates, Life Sciences, Ophthotech, Princeton NJ, Versant Ventures, National blog main, New York blog main, New York top stories, Seattle blog main

Pharma giants like Novartis and Sanofi are betting that the future of healthcare looks more like an app or sensor than a prescription

Drugmakers that got their start making pills and injections worth billions are turning their attention to digital therapeutics, enabled by new technology.  Their thinking is that pharmaceuticals can only take us so far, and it's up to drugmakers and potentially technology companies to come together and figure out how to push that envelope. For instance, Japanese pharma company Otsuka got approval for a version of an antipsychotic drug embedded with a sensor that can tell doctors if you've take...
Tags: Apple, Berlin, Digital, US, Trends, Merck, Pwc, Silicon Valley, Fda, Novartis, Shire, Young, Bayer, Parkinson, Johnson Johnson, Sanofi

Weirdest hotels around the world

The traditional chain hotels , with their cookie-cutter design and bland continental breakfasts are the reason why we tend to spend as little time in our rooms as possible when traveling. Not all hotels, however, are a necessary evil — some are inventive, fun, artsy and destinations in themselves. Whether it’s a hotel with underwater views or one where guests sleep inside massive wine barrels, the following hotels from around the world take the lodging experience to the next level. 1. Kokop...
Tags: Travel, Europe, Sweden, Hobbit, Netherlands, New Zealand, Finland, Shire, New Mexico, Bilbo, British Columbia, Levi, North Island, All, Kokopelli, Vancouver Island

Where I’m At: February, 2019 – Kuala Lumpur edition

Greetings from Kuala Lumpur and another edition of Where I’m At – my monthly summary of where I’ve been and other site news. Where I’ve Been Saigon Apart from the first and last days of January, I spent the whole month in Saigon. I started the month in Pattaya and Bangkok, before returning to Vietnam. Originally I was going to visit the Mekong Delta, but I needed a productive month of not moving around. January is also the best month of the year in Saigon, so I made the most of that. Th...
Tags: Travel, Asia, Southeast Asia, US, Thailand, Malaysia, Kuala Lumpur, Shanghai, Bangladesh, Shire, Vietnam, Bangkok, Macau, Ho Chi Minh City, Where I'm At, Chiang Mai

Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More

Diabetes drugs are Eli Lilly’s bread and butter, but the pharmaceutical giant hasn’t lost its appetite for cancer drugs. It grabbed hold of a few more this week by betting $8 billion on Loxo Oncology.Loxo (NASDAQ: LOXO) has made a name for itself by becoming one of just two companies ever to earn an FDA approval for a drug that targets a tumor’s DNA fingerprint, no matter where in the body that cancer is found. The drug, larotrectinib, targets rare tumor abnormalities known as NTRK fusions. The...
Tags: Deals, Startups, Ipo, Cancer, Trends, Medicare, SEC, Fda, National, GlaxoSmithKline, Allergan, Shire, Biotech, Medical Device, Postpartum Depression, Bernie Sanders

Takeda unlikely to sell OTC drug business - CEO

Takeda Pharmaceutical is unlikely to sell its over-the-counter (OTC) drug business even amid pressure to improve its finances as it closes a $59 billion takeover of London-listed Shire, Chief Executive Christophe Weber said on Monday.
Tags: London, Money, businessNews, Shire, Takeda, Takeda Pharmaceutical, Christophe Weber

Where I’m At: January, 2019 – Pattaya edition

Greetings from Pattaya and happy new year! Hope you all have a great 2019. Where I’m At is my monthly summary of where I’ve been and other site news. I had a busy travel month, and the more I travel the less I write, so more in-depth articles will be posted later. Where I’ve Been Saigon View this post on Instagram An old beauty in District 5, Saigon. A post shared by James Clark (@nomadicnotes) on ...
Tags: Travel, Hong Kong, Thailand, Shire, Bangkok, Macau, Da Nang, Pai, Where I'm At, Chiang Mai, Anthony Bourdain, Pattaya, Saigon, Agoda, Nha Trang, JAMES CLARK

Alternate Histories: The Two Film Adaptations of ‘Lord of the Rings’ on Their 40th and 15th Anniversaries

2018 is a major anniversary for The Lord of the Rings on screen. It’s been 40 years since the release of Ralph Bakshi’s animated version, and 15 years since the completion of Peter Jackson’s live-action trilogy. This dual anniversary – in addition to an imminent new adaptation on Amazon – makes for a fine opportunity to look at the two versions that exist so far. How do they differ? How do they align? Looking back at both from a distance, the answers surprised even me. A Halfling Half-Mo...
Tags: Amazon, Movies, John Lennon, Christopher Lee, Features, Harvey Weinstein, New Zealand, Stanley Kubrick, John, Shire, Jackson, Bilbo, Peter Jackson, Middle Earth, Tolkien, Ralph Bakshi

How to Find the Discipline and Focus to Write

This article is by Anne Marie Gazzolo. I am a master procrastinator and gold-medal winner in the art of distracting myself from what is important. I was so daunted by the amount of notes to gather into a cohesive first draft of my new book, Chosen, about the journeys of Bilbo and Frodo, I put it off again and again. I finally started in January 2017 after I was over the worst of the flu. I had some downtime while I recovered and used it wisely. And guess what? I finished my first draft far soon...
Tags: Facebook, Writing Life, Shire, Resistance, Bilbo, Long Way Home, Frodo, Steven Pressfield, Anne Marie Gazzolo, Pressfield

Healthcare deals hit an all-time record in 2018. See the 7 biggest tie-ups that could change how we buy drugs and treat diseases.

Healthcare dealmaking hit a record this year, and the transactions could reshape how we pay for our prescriptions and treat diseases. Big pharma companies, health insurers, and care providers have agreed to about $421 billion in transactions this year, according to data from Refinitiv. That's a record high, and amounts to 11 percent of all M&A this year. The tally from Refinitiv counts deals when they're announced, though not all transactions are ultimately completed. The dollar figures includ...
Tags: Japan, US, Trends, Cigna, GlaxoSmithKline, Novartis, Shire, GSK, Takeda, Refinitiv

Bio Roundup: ASH Wrap, CRISPR Baby Fallout, Moderna’s Record IPO

The biggest yearly meeting for blood disease research has come and gone, and yet the stories to come out of the American Society of Hematology’s gathering in San Diego represent just a fraction of what happened in biopharma this week.Even if ASH wasn’t on your radar, the CRISPR baby saga—the apparent birth of gene edited twin girls in China that shocked the life sciences world a few weeks ago—rolled on. One massive buyout was signed, and another even bigger one inched closer to being finalized....
Tags: Deals, Startups, China, Ipo, Trends, IPOs, People, Vc, Adhd, San Diego, Astrazeneca, Fda, National, GlaxoSmithKline, Novartis, Ash

Takeda and Shire shareholders back £46bn drugs takeover

Shareholders in Shire and Takeda vote in favour of creating one of the world's biggest pharma groups.
Tags: Business, Shire, Takeda

Shareholders agree to Takeda's $60bn Shire acquisition

Japanese drug giant Takeda's mammoth $60-billion takeover of Irish pharmaceuticals firm Shire has been approved by both sets of shareholders, the pair said Wednesday. The proposed purchase, worth the equivalent of 51.5 billion euros or £46 billion, represents the biggest ever foreign takeover by a Japanese firm. A group of rebel Takeda investors, including members of the founding family, had attempted to thwart the deal but were outvoted at an extraordinary shareholders' meeting held in the w...
Tags: Science, Shire, Osaka, Takeda

Takeda clears key hurdle as investors back $59 billion Shire deal

Takeda Pharmaceutical has won shareholder approval for its $59 billion takeover of London-listed Shire, creating a global powerhouse that has a stronger drugs pipeline but is also saddled with massive debt.
Tags: London, Money, businessNews, Shire, Takeda, Takeda Pharmaceutical

Takeda investors back $59 billion Shire deal, but wary of debt load

Takeda Pharmaceutical shareholders approved on Wednesday its $59 billion takeover of London-listed Shire, creating a global powerhouse with a stronger drugs pipeline but one that is saddled with massive debt.
Tags: London, Money, businessNews, Shire, Takeda, Takeda Pharmaceutical

Takeda shareholders approve $59 billion Shire buy but are wary of debt load

Takeda Pharmaceutical shareholders approved on Wednesday its $59 billion takeover of London-listed Shire, creating a global powerhouse with a stronger drugs pipeline but one that is saddled with massive debt.
Tags: London, Money, businessNews, Shire, Takeda, Takeda Pharmaceutical

Takeda shareholders agree to $60 bn Shire acquisition

Shareholders at Japanese drug giant Takeda on Wednesday approved a plan to buy Irish pharmaceuticals firm Shire in a deal worth around $60 billion, the biggest foreign takeover ever by a Japanese firm. A group of rebel investors, including members of the founding family, tried to thwart the deal but were outvoted at an extraordinary shareholders' meeting held in the western city of Osaka where the company has its headquarters. The scheme was "approved as originally proposed", said a statement...
Tags: Science, Shire, Osaka, Takeda

Takeda gets shareholder approval for £46bn Shire takeover

The move paves the way for Japan's largest overseas acquisition and would create a global drugs giant.
Tags: Japan, UK, News, Shire, Takeda

Takeda shareholders back £46bn Shire takeover

Investor approval paves the way for Japan's largest overseas acquisition and create a global drugs giant.
Tags: Japan, News, Shire, Takeda

Takeda shareholders give nod for $59 billion Shire acquisition

Takeda Pharmaceutical shareholders approved on Wednesday its $59 billion takeover of London-listed Shire, creating a global powerhouse with a stronger drugs pipeline but one that is saddled with massive debt.
Tags: London, Money, businessNews, Shire, Takeda, Takeda Pharmaceutical

Takeda's Shire takeover to bring $963 million fee bonanza

Banks, law firms and other advisers stand to earn up to $963 million in fees from Takeda Pharmaceutical's $62 billion takeover of drugmaker Shire , according to documents for the deal published on Monday.
Tags: Money, businessNews, Shire, Takeda, Takeda Pharmaceutical

100 years on we shall remember them: Britain commemorates its WWI dead

They may no longer be with us - the last of their number, Harry Patch, died in 2009, aged 111 - but we will remember them. Around the country thousands of people will pay tribute on Sunday to those who died on foreign soil or at sea for their country, and those at home who endured the anguish and hardship of global war. On the 100th anniversary of the Armistice events will take place in every corner of the British Isles to commemorate the sacrifice of a generation during the First World War, whi...
Tags: UK, News, Wales, France, Germany, India, Britain, Theresa May, Victoria Cross, Cenotaph, Yorkshire, Cardiff, Devon, Belfast, Westminster, Portsmouth

Ten Reasons Why The Hobbit Trilogy is Worthwhile

Ten Reasons Why the Hobbit Trilogy is Worthwhile The Lord of the Rings trilogy is one of the greatest cinematic achievements of all time.  In terms of fantasy epics, the genre has never been done better. What Peter Jackson was able to pull off with J.R.R. Tolkien’s opus is something we all may never see again in our lifetime.  So when The Hobbit films were announced, all the Middle Earth nerds were incredibly excited.  However, when the first installment was released in December 2012, th...
Tags: Amazon, Movies, Benedict Cumberbatch, The Hobbit, Ed Sheeran, Guillermo Del Toro, Martin Freeman, Shire, Smaug, Jackson, Bilbo, Peter Jackson, Middle Earth, Billy Boyd, Richard Armitage, Tolkien

Exclusive: Takeda to win EU approval for $62 billion Shire deal - sources

Japanese drugmaker Takeda Pharmaceutical is set to win conditional EU antitrust approval for its $62-billion bid for London's Shire, the biggest ever overseas acquisition by a Japanese company, two people familiar with the matter said on Friday.
Tags: London, Money, Eu, businessNews, Shire, Takeda, Takeda Pharmaceutical